Charles Riv Labs Intl Inc Stock Price, News & Analysis

Charles River Laboratories (NYSE: CRL) and CHDI Foundation have announced the extension of their 20-year drug discovery partnership focused on developing treatments for Huntington's disease (HD). The collaboration, which began in 2005, will expand across Charles River's global network and integrate more deeply with CHDI's programs.

The extended partnership encompasses comprehensive services including integrated chemistry, biology, ADME for drug discovery, stem cell research, high-throughput screening, computational chemistry, pharmacology, and biomarker discovery. Over their collaboration, the partnership has yielded 15 composition of matter patent applications and supported research with more than 50 pharma and biotech companies.

The agreement includes data sharing with Charles River's learning algorithms, contributing to the industry's largest dataset while maintaining data protection standards.

Charles River Laboratories (NYSE: CRL) announced its upcoming presentation at the Bank of America 2025 Health Care Conference scheduled for Wednesday, May 14th at 8:40 a.m. PT (11:40 a.m. ET). During the presentation, management will discuss the company's strategic focus, business developments, and recent trends. The presentation will be accessible via live webcast through the Investor Relations section of Charles River's website at ir.criver.com. A replay will be available for at least two weeks after the event.

Charles River Laboratories (NYSE: CRL) announced significant governance updates and a strategic review to enhance stockholder value. The company will appoint four new directors - Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves - while four existing directors will not seek re-election at the 2025 Annual Meeting. The board will be restructured to include eleven directors, with nine being independent.

The company has entered into a Cooperation Agreement with Elliott Investment Management, its largest investor. A Strategic Planning and Capital Allocation Committee will conduct a comprehensive review of Charles River's business and prospects to enhance long-term stockholder value. Additionally, the board will establish a New Approach Methodologies and Science Committee through the merger of existing committees.

Charles River Laboratories has announced the first cohort of its Charles River Incubator Program (CIP), launched in December 2024. The program selected six advanced therapy and technology developers: 64x Bio, Adjuva Bio, Purilogics by Donaldson, Gordian Bio, NanoPalm, and NVI Therapeutics.

Participants will receive mentorship, regulatory expertise, training, and preferential access to Charles River's global facilities. The program focuses on supporting early-stage biotech companies in developing advanced therapies:

• Adjuva Bio: Developing precision-engineered cell therapies for chronic inflammatory diseases
• Gordian Bio: Creating therapeutics using innovative screening platforms
• NanoPalm: Advancing in vivo therapies with AI-designed lipid nanoparticle manufacturing
• NVI Therapeutics: Developing non-viral gene insertion technology
• 64x Bio: Platform for accelerating biologics design and manufacture
• Purilogics: Enhancing biologics purification efficiency

Charles River Laboratories (NYSE: CRL) has announced updates to its oncology drug discovery and development portfolio, highlighting its work on over 80% of FDA-approved cancer therapies in the past five years. The company is expanding its in vitro assays using fully human platforms to enhance therapeutic development.

Key technological advancements include:

• Development of PDX-derived organoids (tumoroids) for more translatable 3D cell cultures
• Implementation of immune-mediated tumor-killing assays
• Enhanced tumor microenvironment targeting capabilities through partnership with Cypre
• Expansion of humanized mice models
• Integration of AI/ML tools through collaborations with Revvity and Aitia

The company offers over 200 RACE Act-compliant pediatric PDX models through the ITCC-P4 consortium, supporting mandatory pediatric testing for oncology drugs. This initiative addresses the critical need for pediatric cancer treatments, as 400,000 children develop cancer annually worldwide, with 25% lacking effective treatment options.

Charles River Laboratories (NYSE: CRL) has announced it will release its first-quarter 2025 financial results on Wednesday, May 7th, before market opening. The company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss the quarterly results. Investors can access the live webcast through the Investor Relations section at ir.criver.com, where a replay will also be available.

Charles River Laboratories (NYSE: CRL) has announced its upcoming presentation at the Barclays 27th Annual Global Healthcare Conference scheduled for Wednesday, March 12th, at 9:30 a.m. ET.

During the presentation, management will provide insights into the company's:

• Strategic focus
• Business developments
• Recent trends

Investors and interested parties can access a live webcast of the presentation through the Investor Relations section at ir.criver.com. A replay will be available on the same platform for a minimum of two weeks following the presentation.

Charles River Laboratories (NYSE: CRL) has entered an agreement with Singapore General Hospital (SGH) to provide CGMP-compliant master cell banking and next-generation sequencing (NGS) services. These services will aid in the characterization of cell lines derived from cord blood for allogeneic CAR-T cell production, aimed at treating cancer patients.

SGH will utilize Charles River's CGMP master cell banking services and NGS-based testing for their upcoming Phase I clinical trials. The NGS technology offers high throughput, scalability, and speed, revolutionizing genetic analysis and pathogen detection. It provides a more efficient and reliable testing option compared to traditional animal-based testing.

Charles River's services ensure compliance with GMP, FDA, EMA, and ICH Q5A and Q5B standards, accelerating development timelines without compromising safety. The company offers a full range of CGMP-compliant cell bank production and storage services, including 9 ISO-6 cleanroom suites and a cell bank completion to release timeline of 8-10 weeks.